UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-38462

NLIGHT, INC.

(Exact name of Registrant as specified in its charter)

Delaware

91-2066376

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification Number)

4637 NW 18th Avenue

Camas, Washington 98607

(Address of principal executive office, including zip code)

(360) 566-4460

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol	Name of Exchange on which Registered
Common Stock, par value $0.0001 per share	LASR	The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☒

Accelerated Filer

☐

Non-Accelerated Filer

☐

Smaller Reporting Company

☐

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August 1,~~October 31, 2022, the Registrant had ~~45,095,519~~45,307,101 shares of common stock outstanding.


TABLE OF CONTENTS
			Page

Part I. Financial Information			1
Item 1. Unaudited Interim Financial Statements			1
Consolidated Balance Sheets: ~~June~~September 30, 2022 and December 31, 2021 (unaudited)			1
Consolidated Statements of Operations: Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2022 and 2021 (unaudited)			2
Consolidated Statements of Comprehensive Loss: Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2022 and 2021 (unaudited)			3
Consolidated Statements of Stockholders' Equity: Three and ~~Six~~Nine Months Ended ~~June~~ September30, 2022 and 2021 (unaudited)			4
Consolidated Statements of Cash Flows: ~~Six~~Nine Months Ended ~~June~~September 30, 2022 and 2021 (unaudited)			6
Notes to Consolidated Financial Statements (unaudited)			7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations			16
Item 3. Quantitative and Qualitative Disclosures About Market Risk			2425
Item 4. Controls and Procedures			2425
Part II. Other Information			26
Item 1. Legal Proceedings			26
Item 1A. Risk Factors			26
Item 6. Exhibits			27
Signatures			28

Table of Contents

PART I

ITEM 1. FINANCIAL STATEMENTS

nLIGHT, Inc.

Consolidated Balance Sheets

(In thousands)

(Unaudited)


		As of					As of
		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021
Assets	Assets					Assets
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	70,633	$	146,534	Cash and cash equivalents	$	62,184	$	146,534
Marketable securities	Marketable securities	50,000		—		Marketable securities	50,190		—
Accounts receivable, net of allowances of $300 and $303		45,944		41,574
Accounts receivable, net of allowances of $287 and $303						Accounts receivable, net of allowances of $287 and $303	43,803		41,574
Inventory	Inventory	80,189		73,746		Inventory	80,660		73,746
Prepaid expenses and other current assets	Prepaid expenses and other current assets	14,617		15,350		Prepaid expenses and other current assets	14,138		15,350
Total current assets	Total current assets	261,383		277,204		Total current assets	250,975		277,204
Restricted cash	Restricted cash	250		250		Restricted cash	251		250
Lease right-of-use assets	Lease right-of-use assets	15,357		17,048		Lease right-of-use assets	14,472		17,048
Property, plant and equipment, net	Property, plant and equipment, net	62,248		56,101		Property, plant and equipment, net	63,232		56,101
Intangible assets, net	Intangible assets, net	5,297		6,698		Intangible assets, net	4,676		6,698
Goodwill	Goodwill	12,359		12,420		Goodwill	12,313		12,420
Other assets, net	Other assets, net	3,580		3,897		Other assets, net	2,634		3,897
Total assets	Total assets	$	360,474	$	373,618	Total assets	$	348,553	$	373,618

Liabilities and Stockholders’ Equity	Liabilities and Stockholders’ Equity					Liabilities and Stockholders’ Equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	23,318	$	26,347	Accounts payable	$	19,755	$	26,347
Accrued liabilities	Accrued liabilities	13,138		14,730		Accrued liabilities	14,548		14,730
Deferred revenues	Deferred revenues	2,034		1,629		Deferred revenues	1,736		1,629
Current portion of lease liabilities	Current portion of lease liabilities	3,032		3,066		Current portion of lease liabilities	2,697		3,066

Total current liabilities	Total current liabilities	41,522		45,772		Total current liabilities	38,736		45,772
Non-current income taxes payable	Non-current income taxes payable	6,991		7,149		Non-current income taxes payable	6,527		7,149
Long-term lease liabilities	Long-term lease liabilities	14,117		14,612		Long-term lease liabilities	13,515		14,612

Other long-term liabilities	Other long-term liabilities	3,990		3,952		Other long-term liabilities	3,937		3,952
Total liabilities	Total liabilities	66,620		71,485		Total liabilities	62,715		71,485
Stockholders' equity:	Stockholders' equity:					Stockholders' equity:

Common stock - $0.0001 par value; 190,000 shares authorized, 45,074 and 44,248 shares issued and outstanding at June 30, 2022, and December 31, 2021, respectively		15		15
Common stock - $0.0001 par value; 190,000 shares authorized, 45,303 and 44,248 shares issued and outstanding at September 30, 2022, and December 31, 2021, respectively						Common stock - $0.0001 par value; 190,000 shares authorized, 45,303 and 44,248 shares issued and outstanding at September 30, 2022, and December 31, 2021, respectively	16		15
Additional paid-in capital	Additional paid-in capital	483,410		470,760		Additional paid-in capital	489,867		470,760
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(2,551)		(587)		Accumulated other comprehensive loss	(4,070)		(587)
Accumulated deficit	Accumulated deficit	(187,020)		(168,055)		Accumulated deficit	(199,975)		(168,055)
Total stockholders’ equity	Total stockholders’ equity	293,854		302,133		Total stockholders’ equity	285,838		302,133
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	360,474	$	373,618	Total liabilities and stockholders’ equity	$	348,553	$	373,618

See accompanying notes to consolidated financial statements.

Table of Contents

nLIGHT, Inc.

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)


		Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,						Nine Months Ended September 30,
		2022		2021		2022		2021				2022		2021			2022		2021
Revenue:	Revenue:										Revenue:
Products	Products	$	48,180	$	53,561	$	99,241	$	100,896		Products	$	48,042	$	54,393		$	147,283	$	155,289
Development	Development	12,647		15,552		26,045		29,562			Development	12,051		17,842			38,096		47,404
Total revenue	Total revenue	60,827		69,113		125,286		130,458			Total revenue	60,093		72,235			185,379		202,693
Cost of revenue:	Cost of revenue:										Cost of revenue:
Products	Products	33,683		34,240		69,451		64,635			Products	35,350		34,193			104,801		98,828
Development	Development	11,759		14,548		24,273		27,853			Development	11,267		16,647			35,540		44,500
Total cost of revenue	Total cost of revenue	45,442		48,788		93,724		92,488			Total cost of revenue	46,617		50,840			140,341		143,328
Gross profit	Gross profit	15,385		20,325		31,562		37,970			Gross profit	13,476		21,395			45,038		59,365
Operating expenses:	Operating expenses:										Operating expenses:
Research and development	Research and development	13,788		14,282		27,499		25,992			Research and development	12,716		14,838			40,215		40,830
Sales, general, and administrative	Sales, general, and administrative	11,914		15,057		22,689		26,771			Sales, general, and administrative	13,741		13,316			36,430		40,087
Total operating expenses	Total operating expenses	25,702		29,339		50,188		52,763			Total operating expenses	26,457		28,154			76,645		80,917
Loss from operations	Loss from operations	(10,317)		(9,014)		(18,626)		(14,793)			Loss from operations	(12,981)		(6,759)			(31,607)		(21,552)
Other income (expense):	Other income (expense):										Other income (expense):
Interest income (expense), net	Interest income (expense), net	71		(32)		71		(106)			Interest income (expense), net	167		(20)			238		(126)
Other income (loss), net	Other income (loss), net	(106)		118		(77)		144			Other income (loss), net	(31)		102			(108)		246
Loss before income taxes	Loss before income taxes	(10,352)		(8,928)		(18,632)		(14,755)			Loss before income taxes	(12,845)		(6,677)			(31,477)		(21,432)
Income tax expense (benefit)	Income tax expense (benefit)	(10)		(1,038)		333		(716)			Income tax expense (benefit)	110		203			443		(513)
Net loss	Net loss	$	(10,342)	$	(7,890)	$	(18,965)	$	(14,039)		Net loss	$	(12,955)	$	(6,880)		$	(31,920)	$	(20,919)

Net loss per share, basic and diluted	Net loss per share, basic and diluted	$	(0.23)	$	(0.19)	$	(0.43)	$	(0.34)		Net loss per share, basic and diluted	$	(0.29)	$	(0.16)		$	(0.72)	$	(0.50)

Shares used in per share calculations, basic and diluted	Shares used in per share calculations, basic and diluted	44,178		42,313		43,919		41,187			Shares used in per share calculations, basic and diluted	44,786		42,884			44,289		41,759

See accompanying notes to consolidated financial statements.

Table of Contents

nLIGHT, Inc.

Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2022		2021		2022		2021
Net loss	Net loss	$	(10,342)	$	(7,890)	$	(18,965)	$	(14,039)	Net loss	$	(12,955)	$	(6,880)	$	(31,920)	$	(20,919)
Other comprehensive loss:	Other comprehensive loss:									Other comprehensive loss:
Foreign currency translation adjustments, net of tax	Foreign currency translation adjustments, net of tax	(1,868)		497		(1,964)		(165)		Foreign currency translation adjustments, net of tax	(1,709)		(378)		(3,673)		(543)
Unrealized gains on available-for-sale securities										Unrealized gains on available-for-sale securities	190		—		190		—
Comprehensive loss	Comprehensive loss	$	(12,210)	$	(7,393)	$	(20,929)	$	(14,204)	Comprehensive loss	$	(14,474)	$	(7,258)	$	(35,403)	$	(21,462)

See accompanying notes to consolidated financial statements.

Table of Contents

nLIGHT, Inc.

Consolidated Statements of Stockholders' Equity

(In thousands)

(Unaudited)


			Three Months Ended June 30, 2022																			Three Months Ended September 30, 2022
		Common stock	Additional paid-in capital			Accumulated other comprehensive loss		Accumulated deficit			Total stockholders' equity							Common stock	Additional paid-in capital	Accumulated other comprehensive loss		Accumulated deficit	Total stockholders' equity
					Shares					Amount											Shares				Accumulated deficit	Amount		Total stockholders' equity

Balance, March 31, 2022			$	44,538		$	15	$	477,924		$	(683)	$	(176,678)	$	300,578
Balance, June 30, 2022																	Balance, June 30, 2022					45,074	$	15					$	483,410	$	(2,551)	$	(187,020)	$	293,854
Net loss	Net loss		—			—		—			—		(10,342)		(10,342)		Net loss					—	—			—			—		(12,955)		(12,955)

Issuance of common stock pursuant to exercise of stock options	Issuance of common stock pursuant to exercise of stock options		48			—		73			—		—		73		Issuance of common stock pursuant to exercise of stock options					86	1			383			—		—		384
Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax	Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax		370			—		(2,468)			—		—		(2,468)		Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax					153	—			(1,421)			—		—		(1,421)

Issuance of common stock under the Employee Stock Purchase Plan			118			—		1,201			—		—		1,201

Restricted stock awards modified in connection with performance achievement																	Restricted stock awards modified in connection with performance achievement					(10)	—			—			—		—		—
Stock-based compensation	Stock-based compensation		—			—		6,680			—		—		6,680		Stock-based compensation					—	—			7,495			—		—		7,495
Unrealized gains on available-for-sale securities																	Unrealized gains on available-for-sale securities					—	—			—			190		—		190
Cumulative translation adjustment, net of tax	Cumulative translation adjustment, net of tax		—			—		—			(1,868)		—		(1,868)		Cumulative translation adjustment, net of tax					—	—			—			(1,709)		—		(1,709)
Balance, June 30, 2022			$	45,074		$	15	$	483,410		$	(2,551)	$	(187,020)	$	293,854
Balance, September 30, 2022																	Balance, September 30, 2022					45,303	$	16		$	489,867		$	(4,070)	$	(199,975)	$	285,838


			Six Months Ended June 30, 2022														Nine Months Ended September 30, 2022
		Common stock		Additional paid-in capital			Accumulated other comprehensive loss		Accumulated deficit		Total stockholders' equity					Common stock	Additional paid-in capital	Accumulated other comprehensive loss		Accumulated deficit		Total stockholders' equity
			Shares			Amount																		Total stockholders' equity
Balance, December 31, 2021	Balance, December 31, 2021		44,248	$	15		$	470,760	$	(587)	$	(168,055)	$	302,133	Balance, December 31, 2021		44,248	$	15	$	470,760	$	(587)			$	302,133
Net loss	Net loss		—	—			—		—		(18,965)		(18,965)		Net loss		—	—		—		—		(31,920)		(31,920)

Issuance of common stock pursuant to exercise of stock options	Issuance of common stock pursuant to exercise of stock options		471	—			762		—		—		762		Issuance of common stock pursuant to exercise of stock options		557	1		1,145		—		—		1,146
Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax	Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax		377	—			(2,546)		—		—		(2,546)		Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax		530	—		(3,967)		—		—		(3,967)
Restricted stock awards forfeited in connection with transition agreement	Restricted stock awards forfeited in connection with transition agreement		(140)	—			—		—		—		—		Restricted stock awards forfeited in connection with transition agreement		(140)	—		—		—		—		—
Restricted stock awards modified in connection with performance achievement															Restricted stock awards modified in connection with performance achievement		(10)	—		—		—		—		—
Issuance of common stock under the Employee Stock Purchase Plan	Issuance of common stock under the Employee Stock Purchase Plan		118	—			1,201		—		—		1,201		Issuance of common stock under the Employee Stock Purchase Plan		118	—		1,201		—		—		1,201
Stock-based compensation	Stock-based compensation		—	—			13,233		—		—		13,233		Stock-based compensation		—	—		20,728		—		—		20,728
Unrealized gains on available-for-sale securities															Unrealized gains on available-for-sale securities		—	—		—		190		—		190
Cumulative translation adjustment, net of tax	Cumulative translation adjustment, net of tax		—	—			—		(1,964)		—		(1,964)		Cumulative translation adjustment, net of tax		—	—		—		(3,673)		—		(3,673)
Balance, June 30, 2022			45,074	$	15		$	483,410	$	(2,551)	$	(187,020)	$	293,854
Balance, September 30, 2022															Balance, September 30, 2022		45,303	$	16	$	489,867	$	(4,070)	$	(199,975)	$	285,838

Table of Contents

nLIGHT, Inc.

Consolidated Statements of Stockholders' Equity

(In thousands)

(Unaudited)


			Three Months Ended June 30, 2021																		Three Months Ended September 30, 2021
		Common stock	Additional paid-in capital		Accumulated other comprehensive loss		Accumulated deficit			Total stockholders' equity							Common stock	Additional paid-in capital	Accumulated other comprehensive loss		Accumulated deficit	Total stockholders' equity
				Shares					Amount											Shares				Accumulated deficit	Amount		Total stockholders' equity

Balance, March 31, 2021			42,783		$	15	$	449,496		$	(921)	$	(144,535)	$	304,055
Balance, June 30, 2021																Balance, June 30, 2021					43,181	$	15					$	457,480	$	(424)	$	(152,425)	$	304,646
Net loss	Net loss		—		—		—			—		(7,890)		(7,890)		Net loss					—	—			—			—		(6,880)		(6,880)
Proceeds from follow-on offering, net of offering costs			—		—		(1)			—		—		(1)
Issuance of common stock pursuant to exercise of stock options	Issuance of common stock pursuant to exercise of stock options		101		—		196			—		—		196		Issuance of common stock pursuant to exercise of stock options					193	—			205			—		—		205
Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax	Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax		264		—		(4,567)			—		—		(4,567)		Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax					502	—			(3,667)			—		—		(3,667)
Issuance of common stock under the Employee Stock Purchase Plan			33		—		750			—		—		750

Stock-based compensation	Stock-based compensation		—		—		11,606			—		—		11,606		Stock-based compensation					—	—			10,072			—		—		10,072
Cumulative translation adjustment, net of tax	Cumulative translation adjustment, net of tax		—		—		—			497		—		497		Cumulative translation adjustment, net of tax					—	—			—			(378)		—		(378)
Balance, Balance, June 30, 2021			43,181		$	15	$	457,480		$	(424)	$	(152,425)	$	304,646
Balance, September 30, 2021																Balance, September 30, 2021					43,876	$	15		$	464,090		$	(802)	$	(159,305)	$	303,998


			Six Months Ended June 30, 2021														Nine Months Ended September 30, 2021
		Common stock		Additional paid-in capital			Accumulated other comprehensive loss		Accumulated deficit		Total stockholders' equity					Common stock	Additional paid-in capital	Accumulated other comprehensive loss		Accumulated deficit		Total stockholders' equity
			Shares			Amount																		Total stockholders' equity
Balance, December 31, 2020	Balance, December 31, 2020		39,793	$	15		$	358,544	$	(259)	$	(138,386)	$	219,914	Balance, December 31, 2020		39,793	$	15	$	358,544	$	(259)			$	219,914
Net loss	Net loss		—	—			—		—		(14,039)		(14,039)		Net loss		—	—		—		—		(20,919)		(20,919)
Proceeds from follow-on offering, net of offering costs	Proceeds from follow-on offering, net of offering costs		2,537	—			82,354		—		—		82,354		Proceeds from follow-on offering, net of offering costs		2,537	—		82,354		—		—		82,354
Issuance of common stock pursuant to exercise of stock options	Issuance of common stock pursuant to exercise of stock options		553	—			770		—		—		770		Issuance of common stock pursuant to exercise of stock options		746	—		975		—		—		975
Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax	Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax		265	—			(4,598)		—		—		(4,598)		Issuance of common stock pursuant to vesting of restricted stock awards and units, net of stock withheld for tax		767	—		(8,265)		—		—		(8,265)
Issuance of common stock under the Employee Stock Purchase Plan	Issuance of common stock under the Employee Stock Purchase Plan		33	—			750		—		—		750		Issuance of common stock under the Employee Stock Purchase Plan		33	—		750		—		—		750
Stock-based compensation	Stock-based compensation		—	—			19,660		—		—		19,660		Stock-based compensation		—	—		29,732		—		—		29,732
Cumulative translation adjustment, net of tax	Cumulative translation adjustment, net of tax		—	—			—		(165)		—		(165)		Cumulative translation adjustment, net of tax		—	—		—		(543)		—		(543)
Balance, Balance, June 30, 2021			43,181	$	15		$	457,480	$	(424)	$	(152,425)	$	304,646
Balance, September 30, 2021															Balance, September 30, 2021		43,876	$	15	$	464,090	$	(802)	$	(159,305)	$	303,998

See accompanying notes to consolidated financial statements.

Table of Contents

nLIGHT, Inc.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)


		Six Months Ended June 30,				Nine Months Ended September 30,
		2022		2021				2022		2021
Cash flows from operating activities:	Cash flows from operating activities:						Cash flows from operating activities:
Net loss	Net loss	$	(18,965)	$	(14,039)		Net loss	$	(31,920)	$	(20,919)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	Adjustments to reconcile net loss to net cash provided by (used in) operating activities:						Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	Depreciation	5,214		4,290			Depreciation	8,135		6,670
Amortization	Amortization	2,329		3,122			Amortization	3,492		4,641
Reduction in carrying amount of right-of-use assets	Reduction in carrying amount of right-of-use assets	1,571		1,632			Reduction in carrying amount of right-of-use assets	2,369		2,435
Provision for (recoveries of) losses on accounts receivable	Provision for (recoveries of) losses on accounts receivable	6		(72)			Provision for (recoveries of) losses on accounts receivable	2		(70)
Stock-based compensation	Stock-based compensation	13,233		19,660			Stock-based compensation	20,728		29,732
Deferred income taxes	Deferred income taxes	(1)		(11)			Deferred income taxes	(1)		(11)
(Gain) Loss on disposal of assets		—		3
Loss on disposal of assets							Loss on disposal of assets	—		3

Unrealized gain on available-for-sale securities							Unrealized gain on available-for-sale securities	(190)		—
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:						Changes in operating assets and liabilities:
Accounts receivable, net	Accounts receivable, net	(4,975)		(4,849)			Accounts receivable, net	(3,431)		(4,580)
Inventory	Inventory	(7,383)		(8,611)			Inventory	(8,761)		(16,169)
Prepaid expenses and other current assets	Prepaid expenses and other current assets	663		175			Prepaid expenses and other current assets	1,091		(5,542)
Other assets, net	Other assets, net	(656)		(905)			Other assets, net	(308)		(437)
Accounts payable	Accounts payable	(1,726)		3,335			Accounts payable	(5,792)		9,699
Accrued and other long-term liabilities	Accrued and other long-term liabilities	(1,191)		1,347			Accrued and other long-term liabilities	1,219		907
Deferred revenues	Deferred revenues	421		133			Deferred revenues	142		(925)
Lease liabilities	Lease liabilities	(409)		(1,404)			Lease liabilities	(1,241)		(2,156)
Non-current income taxes payable	Non-current income taxes payable	104		(721)			Non-current income taxes payable	(86)		(591)
Net cash provided by (used in) operating activities	Net cash provided by (used in) operating activities	(11,765)		3,085			Net cash provided by (used in) operating activities	(14,552)		2,687
Cash flows from investing activities:	Cash flows from investing activities:						Cash flows from investing activities:
Acquisition of business, net of cash acquired	Acquisition of business, net of cash acquired	—		(291)			Acquisition of business, net of cash acquired	(664)		(291)
Purchases of property, plant and equipment	Purchases of property, plant and equipment	(12,893)		(7,962)			Purchases of property, plant and equipment	(16,442)		(13,636)
Acquisition of intangible assets and capitalization of patents	Acquisition of intangible assets and capitalization of patents	(228)		(216)			Acquisition of intangible assets and capitalization of patents	(359)		(303)
Purchase of marketable securities	Purchase of marketable securities	(50,000)		—			Purchase of marketable securities	(50,000)		—

Net cash used in investing activities	Net cash used in investing activities	(63,121)		(8,469)			Net cash used in investing activities	(67,465)		(14,230)
Cash flows from financing activities:	Cash flows from financing activities:						Cash flows from financing activities:
Proceeds from public offerings, net of offering costs	Proceeds from public offerings, net of offering costs	—		82,354			Proceeds from public offerings, net of offering costs	—		82,354

Principal payments on term loan, debt and financing leases	Principal payments on term loan, debt and financing leases	—		(399)			Principal payments on term loan, debt and financing leases	—		(428)
Payment of contingent consideration related to acquisition	Payment of contingent consideration related to acquisition	—		(326)			Payment of contingent consideration related to acquisition	—		(326)

Proceeds from employee stock plan purchases	Proceeds from employee stock plan purchases	1,201		750			Proceeds from employee stock plan purchases	1,201		750

Proceeds from stock option exercises	Proceeds from stock option exercises	762		770			Proceeds from stock option exercises	1,146		975
Tax payments related to stock award issuances	Tax payments related to stock award issuances	(2,546)		(4,598)			Tax payments related to stock award issuances	(3,967)		(8,265)
Net cash provided by (used in) financing activities	Net cash provided by (used in) financing activities	(583)		78,551			Net cash provided by (used in) financing activities	(1,620)		75,060
Effect of exchange rate changes on cash	Effect of exchange rate changes on cash	(432)		(126)			Effect of exchange rate changes on cash	(712)		(256)
Net increase (decrease) in cash, cash equivalents, and restricted cash	Net increase (decrease) in cash, cash equivalents, and restricted cash	(75,901)		73,041			Net increase (decrease) in cash, cash equivalents, and restricted cash	(84,349)		63,261
Cash, cash equivalents, and restricted cash, beginning of period	Cash, cash equivalents, and restricted cash, beginning of period	146,784		102,573			Cash, cash equivalents, and restricted cash, beginning of period	146,784		102,573
Cash, cash equivalents, and restricted cash, end of period	Cash, cash equivalents, and restricted cash, end of period	$	70,883	$	175,614		Cash, cash equivalents, and restricted cash, end of period	$	62,435	$	165,834
Supplemental disclosures:	Supplemental disclosures:						Supplemental disclosures:
Cash paid for interest, net	Cash paid for interest, net	$	—	$	103		Cash paid for interest, net	$	—	$	116
Cash paid for income taxes	Cash paid for income taxes	189		393			Cash paid for income taxes	250		434
Operating cash outflows from operating leases	Operating cash outflows from operating leases	1,914		1,621			Operating cash outflows from operating leases	2,828		2,555
Right-of-use assets obtained in exchange for lease liabilities	Right-of-use assets obtained in exchange for lease liabilities	1,222		7,224			Right-of-use assets obtained in exchange for lease liabilities	2,242		7,348
Accrued purchases of property, equipment and patents	Accrued purchases of property, equipment and patents	1,650		2,139			Accrued purchases of property, equipment and patents	2,468		2,287

See accompanying notes to consolidated financial statements.

Table of Contents

nLIGHT, Inc.

Notes to Consolidated Financial Statements

Note 1 - Basis of Presentation and New Accounting Pronouncements

Basis of Presentation

The accompanying unaudited consolidated financial statements of nLIGHT, Inc. and our wholly-owned subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The unaudited financial information reflects, in the opinion of management, all adjustments necessary for a fair presentation of financial position, results of operations, stockholders’ equity, and cash flows for the interim periods presented. The results reported for the interim period presented are not necessarily indicative of results that may be expected for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Critical Accounting Policies

Our critical accounting policies have not materially changed during the ~~six~~nine months ended ~~June~~September 30, 2022, from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.

New Accounting Pronouncements

None.

Note 2 - Acquisition

On July 30, 2020, we acquired the outstanding shares of OPI Photonics S.r.l. (OPI), an Italian limited liability company, for cash consideration of $1.6 million, $0.2 million of which was paid at closing with the remaining $1.4 million to be paid over ~~the next~~ 24 months.

As The final payment to OPI of ~~June 30, 2022, we owed OPI~~ $0.7 million ~~which~~ was ~~included on our Consolidated Balance Sheets as a component~~made during the third quarter of ~~accrued liabilities.~~2022.

Note 3 - Revenue

We recognize revenue upon transferring control of products and services and the amounts recognized reflect the consideration we expect to be entitled to receive in exchange for these products and services. We consider customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. As part of our consideration of the contract, we evaluate certain factors, including the customer's ability to pay (or credit risk). For each contract, we consider the promise to transfer products, each of which is distinct, as the identified performance obligations.

We allocate the transaction price to each distinct product based on its relative standalone selling price. Master sales agreements or purchase orders from customers could include a single product or multiple products. Regardless, the contracted price with the customer is agreed to at the individual product level outlined in the customer contract or purchase order. We do not bundle prices; however, we do negotiate with customers on pricing for the same products based on a variety of factors (e.g., level of contractual volume). We have concluded that the prices negotiated with each individual customer are representative of the stand-alone selling price of the product.

We often receive orders with multiple delivery dates that may extend across several reporting periods. We allocate the transaction price of the contract to each delivery based on the product standalone selling price and invoice for each scheduled delivery upon shipment or delivery and recognize revenues for such delivery at that point, assuming transfer of control has occurred. Rights of return generally are not included in customer contracts. Accordingly, product revenue is recognized upon shipment or delivery, as applicable, and transfer of control. Rights of return are evaluated as they occur.

Revenues recognized at a point in time consist of sales of semiconductor lasers, fiber lasers and other related products. Revenues recognized over time generally consist of development arrangements that are structured based on our costs incurred. Because control transfers over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. We generally use the cost-to-cost measure of progress for our contracts because it best depicts the transfer of control to the customer. Billing under these arrangements generally occurs within one month after the work is completed.

Table of Contents

The following tables represent a disaggregation of revenue from contracts with customers for the periods presented (in thousands):

Sales by End Market


		Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,						Nine Months Ended September 30,
		2022		2021		2022		2021				2022		2021			2022		2021
Industrial	Industrial	$	21,899	$	24,907	$	45,895	$	46,307		Industrial	$	22,217	$	26,737		$	68,112	$	73,044
Microfabrication	Microfabrication	16,415		20,274		33,734		35,489			Microfabrication	17,682		17,695			51,416		53,184
Aerospace and Defense	Aerospace and Defense	22,513		23,932		45,657		48,662			Aerospace and Defense	20,194		27,803			65,851		76,465
		$	60,827	$	69,113	$	125,286	$	130,458			$	60,093	$	72,235		$	185,379	$	202,693

Sales by Geography


		Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021				2022		2021		2022		2021
North America	North America	$	35,682	$	33,095	$	70,826	$	64,229		North America	$	32,793	$	37,430	$	103,619	$	101,659
China	China	4,672		18,759		11,811		34,336			China	5,230		13,709		17,041		48,045
Rest of World	Rest of World	20,473		17,259		42,649		31,893			Rest of World	22,070		21,096		64,719		52,989
		$	60,827	$	69,113	$	125,286	$	130,458			$	60,093	$	72,235	$	185,379	$	202,693

Sales by Timing of Revenue


		Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021				2022		2021		2022		2021
Point in time	Point in time	$	45,448	$	50,123	$	93,663	$	97,117		Point in time	$	45,268	$	53,070	$	138,931	$	150,187
Over time	Over time	15,379		18,990		31,623		33,341			Over time	14,825		19,165		46,448		52,506
		$	60,827	$	69,113	$	125,286	$	130,458			$	60,093	$	72,235	$	185,379	$	202,693

Our contract assets and liabilities are as follows (in thousands):


		Balance Sheet Classification	As of					Balance Sheet Classification	As of
			June 30, 2022		December 31, 2021				September 30, 2022		December 31, 2021
Contract assets	Contract assets	Prepaid expenses and other current assets	$	7,620	$	9,657	Contract assets	Prepaid expenses and other current assets	$	7,481	$	9,657
Contract liabilities	Contract liabilities	Deferred revenues and other long-term liabilities	3,343		2,358		Contract liabilities	Deferred revenues and other long-term liabilities	2,758		2,358

During the three and ~~six~~nine months ended ~~June~~September 30, 2022, we recognized revenue of $0.1 million and ~~$1.5~~$1.6 million, respectively, that was included in the deferred revenue balances at the beginning of the period as the performance obligations under the associated agreements were satisfied.

Table of Contents

Note 4 - Concentrations of Credit and Other Risks

The following ~~customer~~customers accounted for 10% or more of our revenues for the periods presented:

Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
U.S. Government 16% 20% 16% 20%


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021


U.S. Government	16%	23%	16%	21%



Marubun Corporation	11%	(1)	(1)	(1)

(1)Represents less than 10% of total revenues.

~~Table of Contents~~

Financial instruments that potentially expose us to concentrations of credit risk consist principally of accounts receivable. As of ~~June~~September 30, 2022, and December 31, 2021, ~~two customers~~one customer accounted for approximately ~~27%~~16% and two customers accounted for approximately 33%, respectively, of net accounts receivable. No other customers accounted for 10% or more of net accounts receivable at either date.

Note 5 - Marketable Securities

Marketable securities consist primarily of highly liquid investments with maturities of greater than 90 days when purchased. Our marketable securities are considered available-for-sale as they represent investments of cash and are available for current operations. As such, they are included as current assets on our Consolidated Balance Sheets at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Any unrealized gains and losses that are considered to be other-than-temporary are recorded in other income (loss), net on our Consolidated Statements of Operations. Realized gains and losses on the sale of marketable securities are determined using the specific-identification method and recorded in other income (loss), net on our Consolidated Statements of Operations.

Unrealized gains ~~and losses~~ were ~~immaterial~~$0.2 million in both the three and ~~six~~nine months ended ~~June~~September 30, 2022. These unrealized gains are considered temporary and are reflected in the Statements of Comprehensive Loss.

See Note 6 for additional information.

Note 6 - Fair Value of Financial Instruments

The carrying amounts of certain of our financial instruments, including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities are shown at cost which approximates fair value due to the short-term nature of these instruments. The fair value of our term and revolving loans approximates the carrying value due to the variable market rate used to calculate interest payments.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

•Level 1 Inputs: Observable inputs, such as quoted prices (unadjusted) in active markets for identical assets or liabilities at the measurement date.

•Level 2 Inputs: Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3 Inputs: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Table of Contents

Our financial instruments that are carried at fair value consist of Level 1 assets which include highly liquid investments and bank drafts classified as cash equivalents and marketable securities. Our fair value hierarchy for our financial instruments was as follows (in thousands):

June 30, 2022
Level 1 Level 2 Level 3 Total
Cash Equivalents:
  Money market securities $ 46,977 $ — $ — $ 46,977
  Commercial paper 621 — — 621
47,598 — — 47,598
Marketable Securities:
  U.S. treasuries 50,000 — — 50,000
Total $ 97,598 $ — $ — $ 97,598

~~Table of Contents~~


	September 30, 2022
	Level 1		Level 2		Level 3		Total
Cash Equivalents:
Money market securities	$	39,139	$	—	$	—	$	39,139
Commercial paper	55		—		—		55
	39,194		—		—		39,194
Marketable Securities:
U.S. treasuries	50,190		—		—		50,190
Total	$	89,384	$	—	$	—	$	89,384


	December 31, 2021
	Level 1		Level 2		Level 3		Total
Cash Equivalents:
Money market securities	$	126,900	$	—	$	—	$	126,900
Commercial paper	236		—		—		236
Total	$	127,136	$	—	$	—	$	127,136

Cash Equivalents

The fair value of cash equivalents is determined based on quoted market prices for similar or identical securities.

Marketable Securities

We classify our marketable securities as available-for-sale and value them utilizing a market approach that uses observable inputs without applying significant judgment.

Note 7 - Inventory

Inventory is stated at the lower of average cost (principally standard cost, which approximates actual cost on a first-in, first-out basis) and net realizable value. Inventory includes raw materials and components that may be specialized in nature and subject to obsolescence. On a quarterly basis, we review inventory quantities on hand in comparison to our past consumption, recent purchases, and other factors to determine what inventory quantities, if any, may not be sellable. Based on this analysis, we write down the affected inventory value for estimated excess and obsolescence charges. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

Inventory consisted of the following (in thousands):


		As of					As of
		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021
Raw materials	Raw materials	$	37,681	$	32,185	Raw materials	$	38,404	$	32,185
Work in process and semi-finished goods	Work in process and semi-finished goods	25,454		24,642		Work in process and semi-finished goods	24,213		24,642
Finished goods	Finished goods	17,054		16,919		Finished goods	18,043		16,919
		$	80,189	$	73,746		$	80,660	$	73,746

Note 8 - Property, Plant and Equipment

Property, plant and equipment consist of the following (in thousands):

As of
Useful life (years) June 30, 2022 December 31, 2021
Automobile 3 $ 111 $ 114
Computer hardware and software 3 - 5 8,385 6,594
Manufacturing and lab equipment 2 - 7 87,095 81,130
Office equipment and furniture 5 - 7 2,347 2,361
Leasehold and building improvements 2 - 12 30,471 28,125
Buildings 30 9,392 9,392
Land N/A 3,399 3,399
141,200 131,115
Accumulated depreciation (78,952) (75,014)
$ 62,248 $ 56,101

Table of Contents


		As of
	Useful life (years)	September 30, 2022		December 31, 2021
Automobile	3	$	109	$	114
Computer hardware and software	3 - 5	8,371		6,594
Manufacturing and lab equipment	2 - 7	88,972		81,130
Office equipment and furniture	5 - 7	2,324		2,361
Leasehold and building improvements	2 - 12	30,868		28,125
Buildings	30	9,392		9,392
Land	N/A	3,399		3,399
		143,435		131,115
Accumulated depreciation		(80,203)		(75,014)
		$	63,232	$	56,101

Note 9 - Intangible Assets and Goodwill

~~Intangibles~~Intangible Assets

The details of ~~amortizing~~definite lived intangible assets ~~are~~were as follows (in thousands):


		Estimated useful life (in years)	As of					Estimated useful life (in years)	As of
			June 30, 2022		December 31, 2021				September 30, 2022		December 31, 2021
Patents	Patents	3 - 5	$	6,185	$	5,986	Patents	3 - 5	$	6,288	$	5,986
Development programs	Development programs	2 - 4	7,200		7,200		Development programs	2 - 4	7,200		7,200
Developed technology	Developed technology	5	2,888		3,038		Developed technology	5	2,736		3,038
			16,273		16,224				16,224		16,224
Accumulated amortization	Accumulated amortization		(10,976)		(9,526)		Accumulated amortization		(11,548)		(9,526)
			$	5,297	$	6,698			$	4,676	$	6,698

Amortization related to intangible assets was as follows (in thousands):

Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
Amortization expense $ 711 $ 1,026 $ 1,487 $ 2,042


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Amortization expense	$	660	$	1,026	$	2,147	$	3,068

Estimated amortization expense for future years is as follows (in thousands):

Remainder of 2022 $ 1,433
2023 2,187
2024 879
2025 505
2026 293
$ 5,297


Remainder of 2022	$	737
2023	2,209
2024	900
2025	511
2026	319

	$	4,676

Goodwill

The carrying amount of goodwill by segment iswas as follows (in thousands):


		Laser Products		Advanced Development		Totals			Laser Products		Advanced Development		Totals

Balance, December 31, 2021	Balance, December 31, 2021	2,172		10,248		12,420		Balance, December 31, 2021	2,172		10,248		12,420
Currency exchange rate adjustment	Currency exchange rate adjustment	(61)		—		(61)		Currency exchange rate adjustment	(107)		—		(107)
Balance, June 30, 2022		$	2,111	$	10,248	$	12,359
Balance, September 30, 2022								Balance, September 30, 2022	$	2,065	$	10,248	$	12,313

Table of Contents

Note 10 - Accrued Liabilities

Accrued liabilities consist of the following (in thousands):


		As of					As of
		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021
Accrued payroll and benefits	Accrued payroll and benefits	$	9,192	$	10,915	Accrued payroll and benefits	$	10,492	$	10,915
Product warranty, current	Product warranty, current	2,325		2,286		Product warranty, current	2,491		2,286

Other accrued expenses	Other accrued expenses	1,621		1,529		Other accrued expenses	1,565		1,529
		$	13,138	$	14,730		$	14,548	$	14,730

~~Table of Contents~~

Note 11 - Product Warranties

We provide warranties on certain products and record a liability for the estimated future costs associated with warranty claims at the time revenue is recognized. The warranty liability is based on historical experience, any specifically identified failures, and our estimate of future costs. The current portion of our product warranty liability is included in the accrued liabilities and the long-term portion is included in other long-term liabilities in our Consolidated Balance Sheets.

Product warranty liability activity was as follows for the periods presented (in thousands):


		Six Months Ended June 30,					Nine Months Ended September 30,
		2022		2021			2022		2021
Product warranty liability, beginning	Product warranty liability, beginning	$	5,371	$	4,711	Product warranty liability, beginning	$	5,371	$	4,711
Warranty charges incurred, net	Warranty charges incurred, net	(409)		(1,132)		Warranty charges incurred, net	(1,023)		(1,699)
Provision for warranty charges, net of adjustments	Provision for warranty charges, net of adjustments	198		1,779		Provision for warranty charges, net of adjustments	971		2,431

Product warranty liability, ending	Product warranty liability, ending	5,160		5,358		Product warranty liability, ending	5,319		5,443
Less: current portion of product warranty liability	Less: current portion of product warranty liability	(2,325)		(2,246)		Less: current portion of product warranty liability	(2,491)		(2,251)
Non-current portion of product warranty liability	Non-current portion of product warranty liability	$	2,835	$	3,112	Non-current portion of product warranty liability	$	2,828	$	3,192

Note 12 - Commitments and Contingencies

Leases

See Note 13.

Legal Matters

On March 25, 2022, Lumentum Operations LLC filed a complaint against nLIGHT, Inc. and certain of its employees in the U.S. District Court for the Western District of Washington. The complaint alleges that Lumentum is the partial or full owner of certain of our patents and requests corresponding relief from the court. We ~~intend to~~are vigorously ~~defend~~defending against Lumentum’s allegations.

From time to time, we may be subject to various other legal proceedings and claims in the ordinary course of business. We do not believe the ultimate resolution of these matters will have a material adverse effect on our consolidated financial position, results of operations, or cash flows.

Note 13 - Leases

We lease real estate space under non-cancelable operating lease agreements for commercial and industrial space. Facilities-related operating leases have remaining terms of ~~0.3~~0.1 to ~~12.9~~12.7 years, and some leases include options to extend up to 15 years. Other leases for automobiles, manufacturing and office and computer equipment have remaining lease terms of ~~0.6~~0.3 to ~~3.9~~4.8 years. These leases are primarily operating leases; financing leases are not material. We did not include any renewal options in our lease terms for calculating the lease liabilities as we are not reasonably certain we will exercise the options at this time. The weighted-average remaining lease term for the lease obligations was 8 years as of ~~June~~September 30, 2022, and the weighted-average discount rate was 3.6%.

Table of Contents

The components of lease expense related to operating leases were as follows (in thousands):

Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
Lease expense:
Operating lease expense $ 965 $ 1,092 $ 1,996 $ 1,966
Short-term lease expense 131 210 252 283
Variable and other lease expense 241 235 435 357
$ 1,337 $ 1,537 $ 2,683 $ 2,606


		Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021			2022		2021
Lease expense:
	Operating lease expense	$	911	$	968		$	2,907	$	2,933
	Short-term lease expense	185		172			437		456
	Variable and other lease expense	224		192			659		549
		$	1,320	$	1,332		$	4,003	$	3,938

Future minimum payments under our non-cancelable lease obligations were as follows as of ~~June~~September 30, 2022 (in thousands):

~~Table of Contents~~


Remainder of 2022	Remainder of 2022	$	1,956	Remainder of 2022	$	972
2023	2023	3,234		2023	3,247
2024	2024	2,833		2024	2,854
2025	2025	2,013		2025	2,039
2026	2026	1,631		2026	1,655
Thereafter	Thereafter	8,451		Thereafter	8,461
Total minimum lease payments	Total minimum lease payments	20,118		Total minimum lease payments	19,228
Less: interest	Less: interest	(2,969)		Less: interest	(3,016)
Present value of net minimum lease payments	Present value of net minimum lease payments	17,149		Present value of net minimum lease payments	16,212
Less: current portion of lease liabilities	Less: current portion of lease liabilities	(3,032)		Less: current portion of lease liabilities	(2,697)
Total long-term lease liabilities	Total long-term lease liabilities	$	14,117	Total long-term lease liabilities	$	13,515

Note 14 - Stockholders' Equity and Stock-Based Compensation

Restricted Stock Awards and Units

Restricted stock award (RSA) and restricted stock unit (RSU) activity under our equity incentive plan was as follows (in thousands, except weighted-average grant date fair values):


			Number of Restricted Stock Awards	Weighted-Average Grant Date Fair Value				Number of Restricted Stock Awards	Weighted-Average Grant Date Fair Value
RSAs at December 31, 2021	RSAs at December 31, 2021		753	$	25.63	RSAs at December 31, 2021		753	$	25.63

		Awards vested	(171)	25.10			Awards vested	(271)	22.77
		Awards forfeited	(140)	25.21			Awards forfeited	(140)	25.21
RSAs at June 30, 2022			442	25.97
							Awards modified	(10)	22.54
RSAs at September 30, 2022						RSAs at September 30, 2022		332	28.24

RSAs forfeited were in connection with our former chief financial officer's transition agreement dated January 18, 2022.


			Number of Restricted Stock Units	Weighted-Average Grant Date Fair Value				Number of Restricted Stock Units	Weighted-Average Grant Date Fair Value
RSUs at December 31, 2021	RSUs at December 31, 2021		2,799	$	24.41	RSUs at December 31, 2021		2,799	$	24.41
		Awards granted	78	15.61			Awards granted	1,328	11.67
		Awards vested	(576)	26.47			Awards vested	(839)	23.93
		Awards forfeited	(143)	26.03			Awards forfeited	(167)	25.28
RSUs at June 30, 2022			2,158	23.45
RSUs at September 30, 2022						RSUs at September 30, 2022		3,122	19.09

Table of Contents

The total fair value of RSAs and RSUs vested during the ~~six~~nine months ended ~~June~~September 30, 2022, was ~~$4.3~~$6.2 million and ~~$15.3~~$20.1 million, respectively. Awards outstanding as of ~~June~~September 30, 2022 include ~~0.7 million~~740,199 performance-based awards that will vest upon meeting certain performance criteria.

Stock Options

The following table summarizes our stock option activity during the ~~six~~nine months ended ~~June~~September 30, 2022 (in thousands, except weighted-average exercise prices):

~~Table of Contents~~


		Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value		Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	Outstanding, December 31, 2021	2,454	$1.61	4.4	$54,815	Outstanding, December 31, 2021	2,454	$1.61	4.4	$54,815

Options exercised	Options exercised	(471)	$1.62			Options exercised	(557)	$2.06
Options canceled	Options canceled	(41)	$9.44			Options canceled	(42)	$9.27
Outstanding, June 30, 2022		1,942	$1.44	3.8	$17,037
Options exercisable at June 30, 2022		1,916	$1.41	3.8	$16,890
Options vested as of June 30, 2022, and expected to vest after June 30, 2022		1,942	$1.44	3.8	$17,037
Outstanding, September 30, 2022						Outstanding, September 30, 2022	1,855	$1.31	3.7	$15,116
Options exercisable at September 30, 2022						Options exercisable at September 30, 2022	1,849	$1.28	3.6	$15,111
Options vested as of September 30, 2022, and expected to vest after September 30, 2022						Options vested as of September 30, 2022, and expected to vest after September 30, 2022	1,855	$1.31	3.7	$15,116

Total intrinsic value of options exercised for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, was ~~$6.9~~$7.5 million and ~~$17.8~~$23.3 million, respectively. We received proceeds of ~~$0.8~~$1.1 million and ~~$0.8~~$1.0 million from the exercise of options for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively.

Employee Stock Purchase Plan

Information related to activity under our Employee Stock Purchase Plan was as follows ~~(in thousands, except weighted average per share prices)~~(shares in thousands):






	~~Six~~Nine Months Ended ~~June~~September 30, 2022
Shares issued	118
Weighted-average per share purchase price	$	10.15
Weighted-average per share discount from the fair value of our common stock on date of issuance	$	1.79

Stock-Based Compensation

Total stock-based compensation expense was included in our consolidated statements of operations as follows (in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021				2022		2021		2022		2021
Cost of revenues	Cost of revenues	$	684	$	549	$	1,393	$	1,040		Cost of revenues	$	712	$	740	$	2,105	$	1,780
Research and development	Research and development	3,117		3,708		6,239		6,626			Research and development	3,169		3,782		9,408		10,408
Sales, general and administrative	Sales, general and administrative	2,879		7,349		5,601		11,994			Sales, general and administrative	3,614		5,550		9,215		17,544
		$	6,680	$	11,606	$	13,233	$	19,660			$	7,495	$	10,072	$	20,728	$	29,732

Unrecognized Compensation Costs

As of ~~June~~September 30, 2022, total unrecognized stock-based compensation was ~~$46.1~~$51.6 million, which will be recognized over an average expected recognition period of 2.3 years.

Common Stock Repurchase Plan

On November 14, 2019, our Board of Directors authorized the repurchase of up to $10.0 million of our outstanding shares of common stock. The authorization does not have an expiration date. As of ~~June~~September 30, 2022, no repurchases had been executed under the program.

Table of Contents

Note 15 - Segment Information

We operate in 2two reportable segments consisting of the Laser Products segment and the Advanced Development segment. The following table summarizes the operating results by reportable segment for the periods presented (dollars in thousands):


		Three Months Ended June 30, 2022												Three Months Ended September 30, 2022
		Laser Products			Advanced Development			Corporate and Other		Totals				Laser Products			Advanced Development			Corporate and Other		Totals
Revenue	Revenue	$	48,180		$	12,647		$	—	$	60,827		Revenue	$	48,042		$	12,051		$	—	$	60,093
Gross profit	Gross profit	$	15,182		$	888		$	(685)	$	15,385		Gross profit	$	13,404		$	784		$	(712)	$	13,476
Gross margin	Gross margin	31.5		%	7.0		%	NM		25.3		%	Gross margin	27.9		%	6.5		%	NM*		22.4		%


		Six Months Ended June 30, 2022												Nine Months Ended September 30, 2022
		Laser Products			Advanced Development			Corporate and Other		Totals				Laser Products			Advanced Development			Corporate and Other		Totals
Revenue	Revenue	$	99,241		$	26,045		$	—	$	125,286		Revenue	$	147,283		$	38,096		$	—	$	185,379
Gross profit	Gross profit	$	31,184		$	1,772		$	(1,394)	$	31,562		Gross profit	$	44,587		$	2,556		$	(2,105)	$	45,038
Gross margin	Gross margin	31.4		%	6.8		%	NM		25.2		%	Gross margin	30.3		%	6.7		%	NM*		24.3		%


		Three Months Ended June 30, 2021												Three Months Ended September 30, 2021
		Laser Products			Advanced Development			Corporate and Other		Totals				Laser Products			Advanced Development			Corporate and Other		Totals
Revenue	Revenue	$	53,561		$	15,552		$	—	$	69,113		Revenue	$	54,393		$	17,842		$	—	$	72,235
Gross profit	Gross profit	$	19,871		$	1,004		$	(550)	$	20,325		Gross profit	$	20,940		$	1,195		$	(740)	$	21,395
Gross margin	Gross margin	37.1		%	6.5		%	NM		29.4		%	Gross margin	38.5		%	6.7		%	NM*		29.6		%


		Six Months Ended June 30, 2021												Nine Months Ended September 30, 2021
		Laser Products			Advanced Development			Corporate and Other		Totals				Laser Products			Advanced Development			Corporate and Other		Totals
Revenue	Revenue	$	100,896		$	29,562		$	—	$	130,458		Revenue	$	155,289		$	47,404		$	—	$	202,693
Gross profit	Gross profit	$	37,302		$	1,709		$	(1,041)	$	37,970		Gross profit	$	58,241		$	2,904		$	(1,780)	$	59,365
Gross margin	Gross margin	37.0		%	5.8		%	NM		29.1		%	Gross margin	37.5		%	6.1		%	NM*		29.3		%

*NM = not meaningful

Corporate and Other is unallocated expenses related to stock-based compensation.

There have been no material changes to the geographic locations of our long‑lived assets, net, based on the location of the assets, as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.

Note 16 - Net Loss per Share

Basic and diluted net loss and the number of shares used for basic and diluted net loss calculations were the same for all periods presented because we were in a loss position.

The following potentially dilutive securities were not included in the calculation of diluted shares as the effect would have been anti‑dilutive (in thousands):


		Three Months Ended June 30,		Six Months Ended June 30,		Three Months Ended September 30,			Nine Months Ended September 30,
		2022	2021	2022	2021			2022	2021	2022	2021

Restricted stock units and awards	Restricted stock units and awards	1,158	2,057	1,241	2,182		Restricted stock units and awards	701	2,195	1,046	2,547
Employee stock purchase plan		—	3	—	6

Common stock options	Common stock options	1,745	2,803	1,922	2,803		Common stock options	1,676	2,544	2,052	2,717
		2,903	4,863	3,163	4,991			2,377	4,739	3,098	5,264

Table of Contents

Note 17 - Subsequent Event

In October 2022, we gave notice to employees at our Shanghai manufacturing facility of a reduction in force. A severance charge of approximately $0.9 million will be recorded in the fourth quarter of 2022.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "ability," "anticipate," "attempt," "believe," "can be," "continue," "could," "depend," "enable," "estimate," "expect," "extend," "grow," "if," "intend," "likely," "may," "objective," "ongoing," "plan," "possible," "potential," "predict," "project," "propose," "rely," "should," "target," "will," "would" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements include, but are not limited to, statements about: our business model and strategic plans; the impact ~~on our business from~~of the COVID-19 pandemic and the related lockdown in ~~Shanghai;~~Shanghai on our business; our future financial performance; demand for our semiconductor and fiber laser solutions; our ability to develop innovative products; our expectations regarding product volumes and the introduction of new products; our technology and new product research and development activities; the impact of inflation; the impact of seasonality; the effect on our business of litigation to which we are or may become a party; and the sufficiency of our existing liquidity sources to meet our cash needs.

You should refer to the "Risk Factors" section of this report for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, which although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Overview

nLIGHT, Inc., is a leading provider of high‑power semiconductor and fiber lasers for industrial, microfabrication, and aerospace and defense applications. Headquartered in Camas, Washington, we design, develop, and manufacture the critical elements of our lasers, and believe our vertically integrated business model enables us to rapidly introduce innovative products, control our costs and protect our intellectual property.

We operate in two reportable segments consisting of the Laser Products segment and the Advanced Development segment. Sales of our semiconductor lasers, fiber lasers and directed energy products are included in the Laser Products segment, while revenue earned from research and development contracts are included in the Advanced Development segment.

Revenues decreased to ~~$125.3~~$185.4 million in the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~$130.5~~$202.7 million in the same period of 2021 as a result of a decrease in ~~development revenue and~~ product sales to customers in China ~~that was~~and development

Table of Contents

revenue, partially offset by an increase in product sales to customers outside of China. We generated a net loss of ~~$19.0~~$31.9 million for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to a net loss of ~~$14.0~~$20.9 million for the same period of 2021.

Factors Affecting Our Performance

Impact of the COVID-19 Pandemic

~~Table of Contents~~

The COVID-19 pandemic and related global liquidity concerns and ~~significant~~ macro-economic volatility continues to adversely impact our end-markets, including reduced economic activity and demand for our products, and delays in new capital expenditure decisions and ~~implementations, and restrictions on individual and business activities and travel.~~implementations. While our manufacturing operations ~~have~~ generally remained open throughout the pandemic, including our manufacturing facilities in the United States, ~~which are considered essential businesses,~~ the ~~recent~~ COVID-related lockdown of Shanghai by the Chinese government forced us to halt operations in our Shanghai manufacturing facility for approximately two months during the second quarter ~~during~~of 2022. Our Shanghai facility manufactures products that are sold directly to end customers as well as components that are shipped to our facilities in the United States to be integrated into finished products. Although we are increasing our manufacturing capabilities in the United States, our Shanghai manufacturing facility remains an important part of our global operations.

The closure of our Shanghai facility during the second quarter of 2022 has had a negative impact on our 2022 year-to-date financial results, ~~for the second quarter of 2022,~~ and any additional closures, or partial closures, could have an adverse impact on future periods. In addition to the impact of the lockdown in Shanghai, some of our non-manufacturing personnel have been partially working from home since March 2020. In recent periods, labor issues have become more pronounced as a result of the COVID-19 pandemic and we have experienced higher than expected increases in wages and other compensation costs as well as increased competition for qualified employees.

There are ongoing ~~related~~ risks to our business ~~depending~~that depend on the progression of the COVID-19 pandemic, including ~~from~~risks related to the potential ~~returns to limited or closed~~return of limitations on certain government functions, business activities and person-to-person interactions. Global trade conditions may further adversely impact us and our industry. For example, pandemic-related issues ~~have~~ exacerbated port congestion and caused intermittent supplier shutdowns and delays, resulting in additional expenses and challenges to obtaining critical parts. The full impact of the COVID-19 pandemic on our financial condition and results of operations will depend on future events and developments, such as the duration and magnitude of the pandemic and the conditions and timing under which restrictions will be lifted or re-imposed, impacts on our supply and distribution chains as well as our customers, the demand for our products and whether the pandemic leads to recessionary conditions in any of our key markets.developments.

Demand for our Semiconductor and Fiber Laser Solutions

In order to continue to grow our revenues, we must continue to achieve design wins for our semiconductor and fiber lasers. We consider a design win to occur when a customer notifies us that it has selected one of our products to be incorporated into a product or system under development by such customer. For the foreseeable future, our operations will continue to depend upon capital expenditures by customers in the Industrial and Microfabrication markets, which, in turn, depend upon the demand for these customers’ products or services. In addition, in the Aerospace and Defense market, our business depends in large part on continued investment in laser technology by the U.S. government and its allies, and our ability to continue to successfully develop leading technology in this area and commercialize that technology in the future.

Demand for our products also fluctuates based on market cycles, continuously evolving industry supply chains, trade and tariff terms, as well as evolving competitive dynamics in each of our end-markets. Erosion of average selling prices, or ASPs, of established products is typical in our industry, and the ASPs of our products generally decrease as our products mature. We may also negotiate discounted selling prices from time to time with certain customers that purchase higher volumes, or to penetrate new markets or applications. Historically, we have been able to offset decreasing ASPs by introducing new and higher value products, increasing the sales of our existing products, expanding into new applications and reducing our manufacturing costs. Although we anticipate further increases in product volumes and the continued introduction of new and higher value products, ASP reduction may cause our revenues to decline or grow at a slower rate.

Technology and New Product Development

We invest heavily in the development of our semiconductor, fiber laser and directed energy technologies to provide solutions to our current and future customers. We anticipate that we will continue to invest in research and development to achieve our technology and product roadmap. Our product development is targeted to specific sectors of the market where we believe the power and performance requirements of our products can provide the most benefit. We believe our close coordination with our customers regarding their future product requirements enhances the efficiency of our research and development expenditures.

~~Manufacturing Costs and Gross Margins~~

Table of Contents

Manufacturing Costs and Gross Margins

Our product gross profit, in absolute dollars and as a percentage of revenues, is impacted by our product sales mix, sales volumes, changes in ASPs, production volumes, the corresponding absorption of manufacturing overhead expenses, production costs and manufacturing yields. Our product sales mix can affect gross profits due to variations in profitability related to product configurations and cost profiles, customer volume pricing, availability of competitive products in various markets, and new product introductions, among other factors. Capacity utilization affects our gross margin because we have a high fixed cost base due to our vertically integrated business model. Increases in sales and production volumes drive favorable absorption of fixed costs, improved manufacturing efficiencies and lower production costs. Gross margins may fluctuate from period to period depending on product mix and the level of capacity utilization.

Our Development gross profit varies with the type and terms of contracts, contract volume, project mix, and progress on projects during the period. Most of our Development contracts are structured as cost plus fixed fee due to the technical complexity of the research and development services.

Seasonality

Our quarterly revenues can fluctuate with general economic trends, holidays in foreign countries such as Chinese New Year in the first quarter of our fiscal year, the timing of capital expenditures by our customers, and general economic trends. In addition, as is typical in our industry, we tend to recognize a larger percentage of our quarterly revenues in the last month of the quarter, which may impact our working capital trends.

Results of Operations

The following table sets forth our operating results as a percentage of revenues for the periods indicated (which may not add up due to rounding):


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2022		2021		2022		2021
Revenue:	Revenue:									Revenue:
Products	Products	79.2	%	77.5	%	79.2	%	77.3	%	Products	79.9	%	75.3	%	79.4	%	76.6	%
Development	Development	20.8		22.5		20.8		22.7		Development	20.1		24.7		20.6		23.4
Total revenue	Total revenue	100.0		100.0		100.0		100.0		Total revenue	100.0		100.0		100.0		100.0
Cost of revenue:	Cost of revenue:									Cost of revenue:
Products	Products	55.4		49.5		55.4		49.5		Products	58.8		47.3		56.5		48.8
Development	Development	19.3		21.1		19.4		21.4		Development	18.7		23.1		19.2		21.9
Total cost of revenue	Total cost of revenue	74.7		70.6		74.8		70.9		Total cost of revenue	77.5		70.4		75.7		70.7
Gross profit	Gross profit	25.3		29.4		25.2		29.1		Gross profit	22.5		29.6		24.3		29.3
Operating expenses:	Operating expenses:									Operating expenses:
Research and development	Research and development	22.7		20.7		21.9		19.9		Research and development	21.2		20.5		21.7		20.1
Sales, general, and administrative	Sales, general, and administrative	19.6		21.8		18.1		20.5		Sales, general, and administrative	22.9		18.4		19.7		19.8
Total operating expenses	Total operating expenses	42.3		42.5		40.0		40.4		Total operating expenses	44.1		38.9		41.4		39.9
Loss from operations	Loss from operations	(17.0)		(13.1)		(14.8)		(11.3)		Loss from operations	(21.6)		(9.3)		(17.1)		(10.6)
Other income (expense):	Other income (expense):									Other income (expense):
Interest income (expense), net	Interest income (expense), net	0.1		—		0.1		(0.1)		Interest income (expense), net	0.3		—		0.1		(0.1)
Other income (loss), net	Other income (loss), net	(0.2)		0.2		(0.1)		0.1		Other income (loss), net	(0.1)		0.1		(0.1)		0.1
Loss before income taxes	Loss before income taxes	(17.1)		(12.9)		(14.8)		(11.3)		Loss before income taxes	(21.4)		(9.2)		(17.1)		(10.6)
Income tax expense (benefit)	Income tax expense (benefit)	—		(1.5)		0.3		(0.5)		Income tax expense (benefit)	0.2		0.3		0.2		(0.3)
Net loss	Net loss	(17.1)	%	(11.4)	%	(15.1)	%	(10.8)	%	Net loss	(21.6)	%	(9.5)	%	(17.3)	%	(10.3)	%

Revenues by End Market

Our revenues by end market were as follows for the periods presented (dollars in thousands):

Table of Contents


		Three Months Ended June 30,								Change					Three Months Ended September 30,								Change
		2022		% of Revenue		2021		% of Revenue		$		%			2022		% of Revenue		2021		% of Revenue		$		%
Industrial	Industrial	$	21,899	36.0	%	$	24,907	36.1	%	$	(3,008)	(12.1)	%	Industrial	$	22,217	37.0	%	$	26,737	37.0	%	$	(4,520)	(16.9)	%
Microfabrication	Microfabrication	16,415		27.0		20,274		29.3		(3,859)		(19.0)		Microfabrication	17,682		29.4		17,695		24.5		(13)		(0.1)
Aerospace and Defense	Aerospace and Defense	22,513		37.0		23,932		34.6		(1,419)		(5.9)		Aerospace and Defense	20,194		33.6		27,803		38.5		(7,609)		(27.4)
		$	60,827	100.0	%	$	69,113	100.0	%	$	(8,286)	(12.0)	%		$	60,093	100.0	%	$	72,235	100.0	%	$	(12,142)	(16.8)	%


		Six Months Ended June 30,								Change					Nine Months Ended September 30,								Change
		2022		% of Revenue		2021		% of Revenue		Amount		%			2022		% of Revenue		2021		% of Revenue		Amount		%
Industrial	Industrial	$	45,895	36.6	%	$	46,307	35.5	%	$	(412)	(0.9)	%	Industrial	$	68,112	36.7	%	$	73,044	36.0	%	$	(4,932)	(6.8)	%
Microfabrication	Microfabrication	33,734		26.9		35,489		27.2		(1,755)		(4.9)		Microfabrication	51,416		27.7		53,184		26.2		(1,768)		(3.3)
Aerospace and Defense	Aerospace and Defense	45,657		36.5		48,662		37.3		(3,005)		(6.2)		Aerospace and Defense	65,851		35.5		76,465		37.8		(10,614)		(13.9)
		$	125,286	100.0	%	$	130,458	100.0	%	$	(5,172)	(4.0)	%		$	185,379	100.0	%	$	202,693	100.0	%	$	(17,314)	(8.5)	%

The decreases in revenue from the Industrial and Microfabrication markets for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, were driven by decreases in unit sales in China, partially offset by increases in unit sales outside of China. The closure of our Shanghai facility for approximately two months during the second quarter of 2022 due to the COVID-19 pandemic had a negative impact on year-to-date sales in China. The decreases in revenue from the Aerospace and Defense market for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, were ~~primarily~~ due to decreased activity on research and development ~~contracts.~~contracts, and a decrease in unit sales for the third quarter of 2022 compared to the same period of 2021 due primarily to supply chain disruptions.

Revenues by Segment

Our revenues by segment were as follows for the periods presented (dollars in thousands):


		Three Months Ended June 30,								Change					Three Months Ended September 30,								Change
		2022		% of Revenue		2021		% of Revenue		$		%			2022		% of Revenue		2021		% of Revenue		$		%
Laser Products	Laser Products	$	48,180	79.2	%	$	53,561	77.5	%	$	(5,381)	(10.0)	%	Laser Products	$	48,042	79.9	%	$	54,393	75.3	%	$	(6,351)	(11.7)	%
Advanced Development	Advanced Development	12,647		20.8		15,552		22.5		(2,905)		(18.7)		Advanced Development	12,051		20.1		17,842		24.7		(5,791)		(32.5)
		$	60,827	100.0	%	$	69,113	100.0	%	$	(8,286)	(12.0)	%		$	60,093	100.0	%	$	72,235	100.0	%	$	(12,142)	(16.8)	%


		Six Months Ended June 30,								Change					Nine Months Ended September 30,								Change
		2022		% of Revenue		2021		% of Revenue		Amount		%			2022		% of Revenue		2021		% of Revenue		Amount		%
Laser Products	Laser Products	$	99,241	79.2	%	$	100,896	77.3	%	$	(1,655)	(1.6)	%	Laser Products	$	147,283	79.4	%	$	155,289	76.6	%	$	(8,006)	(5.2)	%
Advanced Development	Advanced Development	26,045		20.8		29,562		22.7		(3,517)		(11.9)		Advanced Development	38,096		20.6		47,404		23.4		(9,308)		(19.6)
		$	125,286	100.0	%	$	130,458	100.0	%	$	(5,172)	(4.0)	%		$	185,379	100.0	%	$	202,693	100.0	%	$	(17,314)	(8.5)	%

The decreases in Laser Products revenue for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, were driven by decreased units sales ~~to the Industrial and Microfabrication markets~~across each end market as discussed above. ~~There was no significant change in Laser Product sales within the Aerospace and Defense market for the three and six months ended June 30, 2022, compared to the same periods of 2021.~~ The decreases in Advanced Development revenue for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, were primarily due to decreased activity on research and development contracts. Most of our Advanced Development revenue is generated from cost plus fixed fee research and development contracts, and all Advanced Development revenue is included in the Aerospace and Defense market.

Revenues by Geographic Region

Our revenues by geographic region were as follows for the periods presented (dollars in thousands):

Table of Contents


		Three Months Ended June 30,								Change					Three Months Ended September 30,								Change
		2022		% of Revenue		2021		% of Revenue		$		%			2022		% of Revenue		2021		% of Revenue		$		%
North America	North America	$	35,682	58.7	%	$	33,095	47.9	%	$	2,587	7.8	%	North America	$	32,793	54.6	%	$	37,430	51.8	%	$	(4,637)	(12.4)	%
China	China	4,672		7.7		18,759		27.1		(14,087)		(75.1)		China	5,230		8.7		13,709		19.0		(8,479)		(61.8)
Rest of World	Rest of World	20,473		33.6		17,259		25.0		3,214		18.6		Rest of World	22,070		36.6		21,096		29.2		974		4.6
		$	60,827	100.0	%	$	69,113	100.0	%	$	(8,286)	(12.0)	%		$	60,093	100.0	%	$	72,235	100.0	%	$	(12,142)	(16.8)	%


		Six Months Ended June 30,								Change					Nine Months Ended September 30,								Change
		2022		% of Revenue		2021		% of Revenue		Amount		%			2022		% of Revenue		2021		% of Revenue		Amount		%
North America	North America	$	70,826	56.5	%	$	64,229	49.2	%	$	6,597	10.3	%	North America	$	103,619	55.9	%	$	101,659	50.2	%	$	6,597	10.3	%
China	China	11,811		9.4		34,336		26.3		(22,525)		(65.6)		China	17,041		9.2		48,045		23.7		(22,525)		(65.6)
Rest of World	Rest of World	42,649		34.1		31,893		24.4		10,756		33.7		Rest of World	64,719		34.9		52,989		26.1		10,756		33.7
		$	125,286	100.0	%	$	130,458	100.0	%	$	(5,172)	(4.0)	%		$	185,379	100.0	%	$	202,693	100.0	%	$	(5,172)	(4.0)	%

Geographic revenue information is based on the location to which we ship our products. The ~~increases~~decrease in ~~both~~ North America ~~and Rest of World~~ revenue for the three ~~and six~~ months ended ~~June~~September 30, 2022, compared to the same ~~periods~~period of 2021, ~~were primarily driven~~is a result of decreased revenue from the Aerospace and Defense market, partially offset by increased revenue from the Industrial and Microfabrication markets. The increase in North America revenue for the nine months ended September 30, 2022, compared to the same period of 2021, was the result of increased revenue from the Industrial and Microfabrication markets, partially offset by ~~a decrease in Development~~decreased revenue from the Aerospace and Defense market.

The increase in Rest of World revenue for the three months ended September 30, 2022, compared to the same period of 2021, was due to increased revenue from the Microfabrication market, partially offset by decreased revenue from the Industrial market. The increase in Rest of World revenue for the nine months ended September 30, 2022, compared to the same period of 2021, was due to increased revenue from the Microfabrication and Industrial markets.

The decreases in China revenue for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, ~~were due to~~was the result of decreased sales in the Industrial and Microfabrication markets, primarily as a result of deteriorating market ~~conditions in the Industrial market.~~conditions. The closure of our Shanghai facility for approximately two months during the second quarter of 2022 due to the COVID-19 pandemic also had a negative impact on year-to-date sales in China.

Cost of Revenues and Gross Margin

Cost of Laser Products revenue consists primarily of manufacturing materials, labor, shipping and handling costs, tariffs and manufacturing-related overhead. We order materials and supplies based on backlog and forecasted demand from our customers. We expense all warranty costs and inventory provisions as cost of revenues.

Cost of Advanced Development revenue consists of materials, labor, subcontracting costs, and an allocation of indirect costs including overhead and general and administrative.

Our gross profit and gross margin were as follows for the periods presented (dollars in thousands):

Three Months Ended June 30, 2022
Laser Products Advanced Development Corporate and Other Total
Gross profit $ 15,182 $ 888 $ (685) $ 15,385
Gross margin 31.5 % 7.0 % NM 25.3 %

Six Months Ended June 30, 2022
Laser Products Advanced Development Corporate and Other Total
Gross profit $ 31,184 $ 1,772 $ (1,394) $ 31,562
Gross margin 31.4 % 6.8 % NM 25.2 %


		Three Months Ended June 30, 2021												Three Months Ended September 30, 2022
		Laser Products			Advanced Development			Corporate and Other		Total				Laser Products			Advanced Development			Corporate and Other		Total
Gross profit	Gross profit	$	19,871		$	1,004		$	(550)	$	20,325		Gross profit	$	13,404		$	784		$	(712)	$	13,476
Gross margin	Gross margin	37.1		%	6.5		%	NM		29.4		%	Gross margin	27.9		%	6.5		%	NM*		22.4		%

Table of Contents


		Six Months Ended June 30, 2021												Nine Months Ended September 30, 2022
		Laser Products			Advanced Development			Corporate and Other		Total				Laser Products			Advanced Development			Corporate and Other		Total
Gross profit	Gross profit	$	37,302		$	1,709		$	(1,041)	$	37,970		Gross profit	$	44,587		$	2,556		$	(2,105)	$	45,038
Gross margin	Gross margin	37.0		%	5.8		%	NM		29.1		%	Gross margin	30.3		%	6.7		%	NM*		24.3		%


	Three Months Ended September 30, 2021
	Laser Products			Advanced Development			Corporate and Other		Total
Gross profit	$	20,940		$	1,195		$	(740)	$	21,395
Gross margin	38.5		%	6.7		%	NM*		29.6		%


	Nine Months Ended September 30, 2021
	Laser Products			Advanced Development			Corporate and Other		Total
Gross profit	$	58,241		$	2,904		$	(1,780)	$	59,365
Gross margin	37.5		%	6.1		%	NM*		29.3		%

*NM = not meaningful

The decreases in Laser Products gross margin for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, were driven by sales mix and decreased factory utilization, of our Shanghai manufacturing facility due to lower sales, and the closure of our Shanghai facility for approximately two months during the second quarter of 2022 due to the COVID-19 pandemic. In addition, Laser Products gross margin was negatively impacted by increased investments in U.S. based manufacturing, and increased production and freight costs, partially offset by an increase in duty reclaim. The ~~increases~~changes in Advanced Development gross margin for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods of 2021, ~~were~~are not material and primarily ~~due to~~the result of changes in the composition of research and development contracts.

Operating Expenses

Our operating expenses were as follows for the periods presented (dollars in thousands):

Research and Development

Three Months Ended June 30, Change
2022 2021 $ %
Research and development $ 13,788 $ 14,282 $ (494) (3.5) %


	Three Months Ended September 30,				Change
	2022		2021		$		%
Research and development	$	12,716	$	14,838	$	(2,122)	(14.3)	%

Six Months Ended June 30, Change
2022 2021 Amount %
Research and development $ 27,499 $ 25,992 $ 1,507 5.8 %


	Nine Months Ended September 30,				Change
	2022		2021		Amount		%
Research and development	$	40,215	$	40,830	$	(615)	(1.5)	%

The decrease in research and development expense for the three months ended ~~June~~September 30, 2022, compared to the same period in 2021, was driven by a decrease in project-related expenses, a decrease in stock-based compensation of $0.6 million, and a decrease in purchased intangible amortization of $0.4 million. The decrease in research and development expense for the nine months ended September 30, 2022, compared to the same period in 2021, was primarily due to a decrease in stock-based compensation of ~~$0.6 million.~~ $1.0 million and a decrease in purchased intangible amortization of $0.8 million, partially offset by an increase in salary costs and project-related expenses.

Sales, General and Administrative


	Three Months Ended September 30,				Change
	2022		2021		$		%
Sales, general, and administrative	$	13,741	$	13,316	$	425	3.2	%

Table of Contents


	Nine Months Ended September 30,				Change
	2022		2021		Amount		%
Sales, general, and administrative	$	36,430	$	40,087	$	(3,657)	(9.1)	%

The increase in ~~research~~sales, general and ~~development~~administrative expense for the ~~six~~three months ended ~~June~~September 30, 2022, compared to the same period in 2021 was primarily due to increases in salary costs, ~~headcount~~professional service fees, facility expenses and ~~project-related expenses~~decreases in administrative cost allocated to ~~support our~~ development ~~efforts,~~projects, partially offset by a decrease in stock-based compensation of ~~$0.4 million, and~~$1.9 million. The decrease ~~in intangible amortization.~~

~~Sales, General and Administrative~~

Three Months Ended June 30, Change
2022 2021 $ %
Sales, general, and administrative $ 11,914 $ 15,057 $ (3,143) (20.9) %

Six Months Ended June 30, Change
2022 2021 Amount %
Sales, general, and administrative $ 22,689 $ 26,771 $ (4,082) (15.2) %

~~The decreases~~ in sales, general and administrative expense for the ~~three and six~~nine months ended ~~June~~September 30, 2022, compared to the same ~~periods~~period in 2021 were ~~primarily due to decreases~~driven by a decrease in stock-based compensation of ~~$4.5~~$8.3 million, ~~and $6.4 million, respectively,~~ partially offset by increases in salary costs, professional service fees, facility expenses and decreases in administrative cost allocated to development projects. The decreases in stock-based compensation ~~expense~~for the three and nine months ended September 30, 2022, compared to the same periods of 2021, were ~~driven by~~the result of forfeitures and decreases in expected achievement related to performance-based stock awards.

~~Table of Contents~~

Interest Income (Expense), net

Three Months Ended June 30, Change
2022 2021 $ %
Interest income (expense), net $ 71 $ (32) $ 103 (321.9)%


	Three Months Ended September 30,				Change
	2022		2021		$		%
Interest income (expense), net	$	167	$	(20)	$	187	935.0%

Six Months Ended June 30, Change
2022 2021 Amount %
Interest income (expense), net $ 71 $ (106) $ 177 (167.0) %


	Nine Months Ended September 30,				Change
	2022		2021		Amount		%
Interest income (expense), net	$	238	$	(126)	$	364	288.9	%

The increase in interest income, ~~(expense),~~ net, for the three and ~~six~~nine months ended ~~June~~September 30, 2022, compared to the same periods in 2021 was driven by increases in interest rates and the investment in marketable securities during the second quarter of ~~2022.~~2022, as well as the payoff of our long-term debt in the third quarter of 2021.

Other Income (Loss), net

Three Months Ended June 30, Change
2022 2021 $ %
Other income (loss), net $ (106) $ 118 $ (224) (189.8)%


	Three Months Ended September 30,				Change
	2022		2021		$		%
Other income (loss), net	$	(31)	$	102	$	(133)	(130.4)%

Six Months Ended June 30, Change
2022 2021 Amount %
Other income (loss), net $ (77) $ 144 $ (221) (153.5) %


	Nine Months Ended September 30,				Change
	2022		2021		Amount		%
Other income (loss), net	$	(108)	$	246	$	(354)	(143.9)	%

Changes in other income (loss), net, are primarily attributable to changes in net realized and unrealized foreign exchange transactions resulting from currency rate fluctuations.

Income Tax Expense (Benefit)

Three Months Ended June 30, Change
2022 2021 $ %
Income tax expense (benefit) $ (10) $ (1,038) $ 1,028 (99.0) %


	Three Months Ended September 30,				Change
	2022		2021		$		%
Income tax expense (benefit)	$	110	$	203	$	(93)	(45.8)	%

Six Months Ended June 30, Change
2022 2021 Amount %
Income tax expense (benefit) $ 333 $ (716) $ 1,049 (146.5) %

Table of Contents


	Nine Months Ended September 30,				Change
	2022		2021		Amount		%
Income tax expense (benefit)	$	443	$	(513)	$	956	186.4	%

We record income tax expense for taxes in our foreign jurisdictions including Finland, Italy, and Korea. While our tax expense is largely dependent on the geographic mix of earnings related to our foreign operations, we also record tax expense for uncertain tax positions taken and associated penalties and interest. We consider all available evidence, both positive and negative, in assessing the extent to which a valuation allowance should be applied against our deferred tax assets. Due to the uncertainty with respect to their ultimate realizability in the United States, Austria, and China, we continue to maintain a full valuation allowance in these jurisdictions as of ~~June~~September 30, 2022.

The ~~increases~~decrease in income tax expense for the three ~~and six~~ months ended ~~June~~September 30, 2022 compared to the same ~~periods~~period of 2021 was driven by lower profitability in foreign jurisdictions, while the increase in income tax expense for the nine months ended September 30, 2022, compared to the same period in 2021, ~~were~~was driven by a ~~large~~ discrete tax benefit related to return to provision true ups and expiring statutes of limitations of unrecognized tax positions recorded in Q2the second quarter of 2021.

~~Table of Contents~~

Liquidity and Capital Resources

We had cash and cash equivalents of ~~$70.6~~$62.2 million and $146.5 million as of ~~June~~September 30, 2022 and December 31, 2021, respectively. In addition, we had marketable securities of ~~$50.0~~$50.2 million at ~~June~~September 30, 2022. Prior to the second quarter of 2022, we had no marketable securities.

For the ~~six~~nine months ended ~~June~~September 30, 2022, our principal uses of liquidity were to fund our working capital needs and purchase property, plant and equipment. We believe our existing sources of liquidity will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months. Our future capital requirements may vary materially from period to period and will depend on many factors, including the timing and extent of spending on research and development efforts, the expansion of sales and marketing activities, the continuing market acceptance of our products and ongoing investments to support the growth of our business. We may in the future enter into arrangements to acquire or invest in complementary businesses, services, technologies and intellectual property rights. From time to time, we may explore additional financing sources which could include equity, equity‑linked and debt financing arrangements.

The following table summarizes our cash flows for the periods presented (in thousands):


		Six Months Ended June 30,				Nine Months Ended September 30,
		2022		2021				2022		2021
Net cash provided by (used in) operating activities	Net cash provided by (used in) operating activities	$	(11,765)	$	3,085		Net cash provided by (used in) operating activities	$	(14,552)	$	2,687
Net cash used in investing activities	Net cash used in investing activities	(63,121)		(8,469)			Net cash used in investing activities	(67,465)		(14,230)
Net cash provided by (used in) financing activities	Net cash provided by (used in) financing activities	(583)		78,551			Net cash provided by (used in) financing activities	(1,620)		75,060
Effect of exchange rate changes on cash	Effect of exchange rate changes on cash	(432)		(126)			Effect of exchange rate changes on cash	(712)		(256)
Net increase (decrease) in cash, cash equivalents and restricted cash	Net increase (decrease) in cash, cash equivalents and restricted cash	$	(75,901)	$	73,041		Net increase (decrease) in cash, cash equivalents and restricted cash	$	(84,349)	$	63,261

Table of Contents

Net Cash Provided by (Used in) Operating Activities

During the ~~six~~nine months ended ~~June~~September 30, 2022, net cash used in operating activities was ~~$11.8~~$14.6 million, which was the result of a ~~$19.0~~$31.9 million net loss and use of cash for working capital of ~~$15.2~~$17.2 million, partially offset by non‑cash expenses totaling ~~$22.4~~$34.7 million related primarily to depreciation, amortization, and stock-based compensation. Changes in working capital were driven by a ~~$5.0~~$3.4 million increase in accounts receivable, net, a ~~$7.4~~$8.8 million increase in inventory, and a ~~$1.7~~$5.8 million decrease in accounts payable. The increase in accounts receivable, net was primarily due to the timing of shipments and collections in the ~~second~~third quarter of 2022 compared to the fourth quarter of 2021. The increase in inventory was due to an expected increase in future sales and an increase in safety stock during 2022 to mitigate supply chain risks, lower demand primarily from China, and anticipated demand for recently introduced products. The decrease in accounts payable was due to a decrease in inventory purchasing in the third quarter of 2022 compared to the fourth quarter of 2021, and the timing of vendor payments.

During the ~~six~~nine months ended ~~June~~September 30, 2021, net cash provided by operating activities was ~~$3.1~~$2.7 million, which was primarily driven by non‑cash expenses totaling ~~$28.6~~$43.4 million related to depreciation and amortization, stock-based compensation, and other items, a ~~$3.3~~$9.7 million increase in accounts payable and a ~~$1.3~~$0.9 million increase in accrued and other long-term liabilities. These items were partially offset by our net loss of ~~$14.0~~$20.9 million and increases of ~~$8.6~~$16.2 million in inventory and ~~$4.8~~$4.6 million in accounts receivable. The increase in inventory was driven primarily by an expected increase in future period ~~sales, the~~sales. The increase in accounts receivable was attributable to the increase in revenue and timing of shipments during the ~~quarter, and the~~quarter. The increase in accounts payable was attributable to the increase in inventory and the timing of vendor payments.

Net Cash Used in Investing Activities

During the ~~six~~nine months ended ~~June~~September 30, 2022, net cash used in investing activities was ~~$63.1~~$67.5 million, primarily resulting from the purchase of $50.0 million of marketable securities and ~~$12.9~~$16.4 million of capital expenditures related to investments in directed energy, manufacturing equipment and facilities.

During the ~~six~~nine months ended ~~June~~September 30, 2021, net cash used in investing activities was ~~$8.5~~$14.2 million, primarily

resulting from ~~$8.0~~$13.6 million of capital expenditures related to investments in manufacturing equipment and improvements to our corporate facility.

~~Table of Contents~~

Net Cash Provided by (Used in) Financing Activities

During the ~~six~~nine months ended ~~June~~September 30, 2022, net cash used in financing activities was ~~$0.6~~$1.6 million, which was primarily driven by ~~$2.5~~$4.0 million of withholding tax payments related to the vesting of stock awards, partially offset by ~~$2.0~~$2.3 million of proceeds from stock options exercises and employee stock plan purchases.

During the ~~six~~nine months ended ~~June~~September 30, 2021, net cash provided by financing activities was ~~$78.6~~$75.1 million, which was primarily driven by our follow-on public offering of $82.4 million, net of offering costs, and ~~$1.5~~$1.7 million of proceeds from stock options exercises and employee stock program purchases, partially offset by ~~$4.6~~$8.3 million of withholding tax payments related to the vesting of stock awards.

Credit Facilities

We have a $40.0 million revolving line of credit, or LOC, with Pacific Western Bank dated September 24, 2018, which is secured by our assets and matures September 24, 2024.

The LOC agreement contains restrictive and financial covenants and bears an unused credit fee of 0.20% on an annualized basis. The interest rate on the LOC is based on the Prime Rate, minus a margin based on our liquidity levels. No amounts were outstanding under the LOC at ~~June~~September 30, 2022 and we were in compliance with all covenants.

Contractual Obligations

For the ~~six~~nine months ended ~~June~~September 30, 2022, our operating lease obligations decreased by approximately ~~$0.5~~$1.5 million. There have been no other material changes to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.

Table of Contents

Inflation

While we do not believe that inflation had a material effect on our business, financial condition or results of operations through ~~June~~September 30, 2022, we have experienced higher than expected increases in wages and other compensation costs, materials, and shipping costs ~~over the past year.~~during 2022. We expect these increases will continue to impact our cost structure. If our costs become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could materially adversely affect our business, financial condition and results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” contained in Part II of our Annual Report on Form 10-K for the year ended December 31, 2021. Other than the addition of marketable securities consisting of U.S. Treasuries to our investment portfolio, our exposure to market risk has not changed materially since December 31, 2021.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and our chief financial officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our chief executive officer and our chief financial officer have concluded that, as of such date, our disclosure controls and procedures were, in design and operation, effective.

Changes in Internal Control over Financial Reporting

Our chief executive officer and our chief financial officer did not identify any changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act during the three months ended ~~June~~September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~Table of Contents~~

Limitations on the Effectiveness of Internal Control

Control systems, including ours, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems’ objectives are being met. Further, the design of any control systems must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based, in part, on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.

Table of Contents

PART II

ITEM 1. LEGAL PROCEEDINGS

For a description of our material pending legal proceedings, see Note 12, Commitments and Contingencies, to our consolidated financial statements included elsewhere in this report.

ITEM 1A. RISK FACTORS

For risk factors related to our business, reference is made to Item 1A, "Risk Factors," contained in Part I of our Annual Report on Form 10-K for the year ended December 31, 2021 and Item 1A, ~~“Risk~~"Risk Factors,”" contained in Part II of our Quarterly Report on Form 10-Q for the quarter ended ~~March 31,~~June 30, 2022. There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the quarter ended ~~March 31,~~June 30, 2022. , except as described below.

~~The COVID-19 pandemic has disrupted~~We are subject to governmental export and import controls that could subject us to liability, impair our ~~operations, manufacturing~~ability to compete and ~~supply chain and likely will continue to~~otherwise adversely affect our business, financial condition, results of operations and ~~operating results.~~growth prospects.

The ~~COVID-19 pandemic~~United States and related global liquidity concerns and significant macro-economic volatility continues to adversely impact our end-markets, including reduced economic activity and demand for our products, delays in new capital expenditure decisions and implementations,various foreign governments have imposed controls, export license requirements and restrictions on ~~individual~~the import or export of certain products, technologies, and ~~business activities~~software. For example, the U.S. government recently announced new controls restricting the ability to send certain products and ~~travel. Government imposed restrictions~~technology related to semiconductors, semiconductor manufacturing and supercomputing to China without an export license. These new controls including the licensing requirement also apply to certain hardware containing these specified integrated circuits, or ICs. In many cases, these licenses are subject to a policy of denial and will not be issued. The U.S. government also recently added additional entities in China to restricted party lists impacting the ability of U.S. companies to provide products and technology to these entities. These controls may ~~limit~~impact our ability to ~~manufacture~~export certain products and technology to China and restrict our ability to use certain ICs in our products. Additionally, these restrictions could disrupt the ability of China to produce semiconductors and other electronics and impact our ability to source components from China. It also is possible that the Chinese government will retaliate in ways that could impact our business.

We must export our products in ~~a timely manner~~compliance with U.S. export controls and we may not always be successful in obtaining necessary export licenses. Denials of export licenses or ~~at all,~~limitations imposed on our ability to export or sell our products imposed by these laws, may harm our international and ~~some~~domestic revenues. Furthermore, noncompliance with these laws could have negative consequences, including government investigations, penalties and reputational harm. Any failure to adequately comply with these laws could result in civil fines or suspension or loss of our non-manufacturing personnel have been partially working from home since March 2020. The recent COVID-related lockdown of Shanghai by the Chinese government forced us to halt operations in our Shanghai manufacturing for approximately two months during the second quarter of 2022. Our Shanghai facility manufactures products that are sold directly to end customersexport privileges, as well as components that are shipped to our facilities in the United States to be integrated into finished products. Although we are increasing our manufacturing capabilities in the United States, our Shanghai manufacturing facility remains an important partsubstantial expense and diversion of ~~our global operations. Any additional closures, or partial closures,~~management resources and attention, any of ~~our Shanghai facility in the future~~which could ~~have an adverse impact on future periods.~~

In addition, travel has been severely limited during the COVID-19 pandemic due to government restrictions and other precautionary measures. Limitations on travel, for example, have impacted our management’s ability to visit our employees and facilities, particularly in China, as well as our vendors and potential and existing customers. Such limitations havematerially adversely ~~impacted and could continue to adversely impact oversight of our employees and facilities, our sales and marketing efforts, and our manufacturing and supply arrangements, potentially disrupting~~affect our business, financial condition, results of operations and adversely impacting our financial condition and operating results. In recent periods, labor issues have also become more pronounced as a result of the COVID-19 pandemic and we have experienced higher than expected increases in wages and other compensation costs as well as increased competition for qualified employees.

growth prospects.

Table of Contents

ITEM 6. EXHIBITS

(a) Exhibits

Exhibit
Number

Incorporated by Reference

Filed
Herewith

Description

Form

File No.

Exhibit

Filing Date

3.1

Amended and Restated Certificate of Incorporation of the Registrant

10-Q

001-38462

3.1

May 25, 2018

3.2

Amended and Restated Bylaws of the Registrant

8-K

001-38462

3.1

April 21, 2020

4.1

Specimen Common Stock Certificate of the Registrant

S-1/A

333-224055

4.1

April 16, 2018

10.1

2018 Equity Incentive Plan—Form of Restricted Stock Unit Agreement (Performance-Based)

8-K

001-38462

10.1

July 8, 2022

31.1

Certification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


+			Indicates a management contract or compensatory plan or arrangement.
*			The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		NLIGHT, INC.
		(Registrant)


~~August 5,~~November 4, 2022	By:	/s/ SCOTT KEENEY
Date		Scott Keeney
		President and Chief Executive Officer (Principal Executive Officer)

~~August 5,~~November 4, 2022	By:	/s/ JOSEPH CORSO
Date		Joseph Corso
		Chief Financial Officer (Principal Financial Officer)

~~August 5,~~November 4, 2022	By:	/s/ JAMES NIAS
Date		James Nias
		Chief Accounting Officer (Principal Accounting Officer)